Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL13AP23 (ribosomal protein L13a pseudogene 23) is a processed pseudogene on the human genome and does not encode a functional protein. It arises from duplication and retrotransposition of the parental RPL13A gene, which encodes a component of the 60S ribosomal subunit required for protein translation. Like many pseudogenes, RPL13AP23 is dispersed in the genome and is not known to have any direct biological function, disease role, or drug interaction. Pseudogenes such as RPL13AP23 may be transcribed in some contexts, but lack capacity to produce functional proteins and are not considered therapeutic targets. If you intended a search for the functional ribosomal protein L13a or its related gene, see "Ribosomal protein L13a" (RPL13A), which is a structural ribosomal protein and has documented biological and disease-related roles. The current query about RPL13AP23 refers specifically to the pseudogene, not the protein-coding gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L13a pseudogene 23 (RPL13AP23).